Seyedeh Hoda Alavizadeh | Pharmaceutical Science | Best Researcher Award

Posted on by sciencefather

Assist Prof Dr. Seyedeh Hoda Alavizadeh | Pharmaceutical Science | Best Researcher Award

Assistant professor at Pharmaceutical Nanotechnology Department, School of Pharmacy, Mashhad University of Medical Sciences, Iran.

Seyedeh Hoda Alavizadeh is an accomplished assistant professor in pharmaceutical nanotechnology at Mashhad University of Medical Sciences, Iran. Her research focuses on innovative drug delivery systems, particularly liposomal formulations for targeted cancer therapy and neurodegenerative diseases. She has a strong academic background with a Pharm.D. and Ph.D. from MUMS, along with numerous honors including fellowships, grants, and awards like being recognized in the top 1% worldwide for her research. Her leadership extends to organizing international conferences and serving as a CRS ambassador. Alavizadeh’s contributions to pharmaceutical sciences are marked by her extensive publication record and active role in international collaborations and editorial activities.

Professional Profiles:

Education 🎓

Seyedeh Hoda Alavizadeh completed her Ph.D. in Pharmaceutical Nanotechnology at the School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. Her doctoral research focused on the formulation and characterization of temperature-sensitive nanoliposomal cisplatin targeted with anti-Her-2/neu affibody, investigating its antitumor effects with local hyperthermia in vitro and in vivo using mouse tumor models. Under the guidance of Prof. Mahmoud Reza Jaafari, her work contributed significantly to understanding drug delivery mechanisms in cancer treatment. Prior to her Ph.D., she obtained her Pharm. D. from the same institution, specializing in vaccine delivery against leishmaniasis, supervised by Prof. Ali Khamesipour, Prof. Mahmoud Reza Jaafari, and Dr. Ali Badiee. Her Pharm. D. thesis focused on evaluating immune responses in mice inoculated with L. major mixed with LPD nanoparticles containing CpG ODN, demonstrating her early commitment to innovative pharmaceutical research.

Professional Experience

Since completing her education, Seyedeh Hoda Alavizadeh has served as an Assistant Professor at the Pharmaceutical Nanotechnology Department, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. Her interdisciplinary research is grounded in innovation and quality, focusing on developing tumor microenvironment-responsive liposomes for anti-cancer drug delivery. Her expertise includes the formulation of triggered-release liposomes—such as thermo, REDOX, and pH-sensitive formulations—tailored to the tumor microenvironment for cancer therapy and chemo-immunotherapy. She has been actively involved in teaching courses on pharmacy practice, basic biochemistry, biology, cell culture, and advanced topics in drug delivery using nanoparticles.

Research Interest

Seyedeh Hoda Alavizadeh’s research interests are centered on pharmaceutical nanotechnology, with a focus on developing advanced liposomal formulations for targeted drug delivery in cancer therapy. Her research explores triggered-release systems responsive to the tumor microenvironment, including thermo-sensitive, REDOX-sensitive, and pH-sensitive formulations. She is particularly interested in enhancing the efficacy of chemotherapy through innovative liposomal designs and investigating their applications in chemo-immunotherapy. Additionally, she is passionate about developing liposomal formulations of phytochemicals for their antioxidant and neuroprotective roles in diseases like Alzheimer’s and Parkinson’s, contributing to advancements in nanomedicine for therapeutic interventions.

Award and Honors

Seyedeh Hoda Alavizadeh has been recognized with several prestigious honors and awards throughout her career. She served as a CRS Ambassador from 2021 to 2023, promoting excellence in controlled release science. In 2020, she was awarded the Fellowship of the CLINAM Conference and Exhibition, held in Basel, Switzerland, highlighting her contributions to nanomedicine research. Her academic pursuits were further supported by the DAAD Scholarship for the ProGRANT proposal writing course in 2018 and the NIMAD research grant in the same year. Notably, she received the Best Poster Presentation Award at the CLINAM10th Conference and Exhibition in 2017 and was also honored with a Fellowship at the same event, recognizing her impactful research contributions. In 2016, her work was distinguished globally, ranking in the top 1% of papers by Essential Science Indicator of Thomson Reuters ISI, underscoring her significant scholarly impact.

Research Skills

Seyedeh Hoda Alavizadeh possesses a robust skill set in pharmaceutical nanotechnology, focusing on advanced drug delivery systems. Her expertise spans the development of liposomal formulations tailored for targeted delivery of chemotherapeutic agents and phytochemicals, leveraging innovative strategies such as thermo-responsive, REDOX-sensitive, and pH-sensitive mechanisms to optimize drug efficacy while minimizing adverse effects. With a comprehensive understanding of biochemical assays, she proficiently evaluates drug encapsulation efficiencies, release kinetics, and therapeutic outcomes in experimental models. Her academic leadership is evident through roles like vice-scientific chair for the ICNN2021 conference, underscoring her organizational acumen and commitment to advancing nanoscience and nanotechnology. Additionally, her active involvement in international collaborations and editorial responsibilities showcases her dedication to peer-reviewed research and scientific excellence in pharmaceutics and nanomedicine.

Publications

  • Bioactivity assessment and toxicity of crocin: a comprehensive review
    • Authors: SH Alavizadeh, H Hosseinzadeh
    • Year: 2014
    • Citations: 422
  • Novel nanomicelle formulation to enhance bioavailability and stability of curcuminoids
    • Authors: M Hatamipour, A Sahebkar, SH Alavizadeh, M Dorri, MR Jaafari
    • Year: 2019
    • Citations: 102
  • Antitumor activity of PEGylated nanoliposomes containing crocin in mice bearing C26 colon carcinoma
    • Authors: M Rastgoo, H Hosseinzadeh, H Alavizadeh, A Abbasi, Z Ayati, MR Jaafari
    • Year: 2013
    • Citations: 90
  • Redox-sensitive nanoscale drug delivery systems for cancer treatment
    • Authors: E Mirhadi, M Mashreghi, MF Maleki, SH Alavizadeh, L Arabi, A Badiee, …
    • Year: 2020
    • Citations: 80
  • Induction of protection against leishmaniasis in susceptible BALB/c mice using simple DOTAP cationic nanoliposomes containing soluble Leishmania antigen (SLA)
    • Authors: H Firouzmand, A Badiee, A Khamesipour, VH Shargh, SH Alavizadeh, …
    • Year: 2013
    • Citations: 63
  • Improved therapeutic activity of HER2 Affibody-targeted cisplatin liposomes in HER2-expressing breast tumor models
    • Authors: SH Alavizadeh, J Akhtari, A Badiee, S Golmohammadzadeh, MR Jaafari
    • Year: 2016
    • Citations: 56
  • Targeting, biodistribution and tumor growth inhibiting characterization of anti-HER2 affibody coupling to liposomal doxorubicin using BALB/c mice bearing TUBO tumors
    • Authors: J Akhtari, SM Rezayat, M Teymouri, SH Alavizadeh, F Gheybi, A Badiee, …
    • Year: 2016
    • Citations: 48
  • Development of a topical liposomal formulation of Amphotericin B for the treatment of cutaneous leishmaniasis
    • Authors: MR Jaafari, M Hatamipour, SH Alavizadeh, A Abbasi, Z Saberi, S Rafati, …
    • Year: 2019
    • Citations: 46
  • The influence of phospholipid on the physicochemical properties and anti-tumor efficacy of liposomes encapsulating cisplatin in mice bearing C26 colon carcinoma
    • Authors: SH Alavizadeh, A Badiee, S Golmohammadzadeh, MR Jaafari
    • Year: 2014
    • Citations: 46
  • Development of topical liposomes containing miltefosine for the treatment of Leishmania major infection in susceptible BALB/c mice
    • Authors: Z Kavian, SH Alavizadeh, S Golmohamadzadeh, A Badiee, …
    • Year: 2019
    • Citations: 40
  • The molecular mechanisms of curcumin’s inhibitory effects on cancer stem cells
    • Authors: E Zendehdel, E Abdollahi, AA Momtazi‐Borojeni, M Korani, …
    • Year: 2019
    • Citations: 34

 

Amedeo De Nicolò | Pharmaceutical Science | Best Researcher Award

Posted on by sciencefather

Dr. Amedeo De Nicolò | Pharmaceutical Science | Best Researcher Award

Ricercatore a Tempo Determinato Cat. B at University of Turin, Italy.

Amedeo De Nicolò, born on April 20, 1987, is an Italian researcher currently affiliated with the University of Turin. He holds a PhD in Medicine and Experimental Therapy and a Master’s degree in Cellular and Molecular Biology. De Nicolò specializes in pharmacology, focusing on pharmacokinetics and pharmacogenetics. His research interests include developing bioanalytical methods for Therapeutic Drug Monitoring (TDM) and studying drug interactions and pharmacokinetic/pharmacodynamic evaluations. Throughout his career, he has contributed significantly to clinical pharmacology through various research projects, publications, and participation in international collaborations. In addition to his research, De Nicolò has a strong teaching background, having taught pharmacology courses at the University of Turin and participated in a Master’s program related to biological product control in the industry. He is also an active member of several scientific societies and working groups, including the Italian Society of Pharmacology and the international research consortium VirTUAL.

Professional Profiles:

Education

Amedeo De Nicolò completed his PhD in Medicine and Experimental Therapy from the University of Turin in January 2017. His dissertation focused on the “Pharmacokinetics and Pharmacogenetics of Anti-HCV Treatments,” receiving positive evaluations. Prior to his doctorate, he earned a Master’s degree in Cellular and Molecular Biology, with a Biomedical curriculum, from the same university in October 2011. His master’s thesis titled “Identificazione di Nuovi Parametri Farmacocinetici per la Valutazione Precoce del Rischio di Anemizzazione in Pazienti Sottoposti a Terapia Anti-HCV Standard” was awarded the highest honors, graduating with a score of 110/110 cum laude. Additionally, he holds a Bachelor’s degree in Biological Sciences from the University of Turin, obtained in December 2009. Throughout his academic journey, De Nicolò acquired substantial competencies in biological sciences, clinical pharmacology, laboratory medicine, and statistics. In August 2020, he also achieved professional licensure as a Biologist, further solidifying his qualifications in the field.

Professional Experience

Amedeo De Nicolò is currently a fixed-term researcher (type B) at the University of Turin, specializing in pharmacokinetics and pharmacogenetics. He has been involved in clinical pharmacology research since his internship for his master’s thesis in 2010-2011. From March 2022, he has held his current position at the Department of Medical Sciences, focusing on the development, validation, and application of bioanalytical methods in liquid chromatography for Therapeutic Drug Monitoring (TDM). Prior to this, he was a research fellow from July 2017 to February 2022 at the same institution. During this period, he contributed significantly to pharmacokinetic studies, particularly related to drug-drug interactions and the pharmacokinetic/pharmacodynamic evaluations of antiviral and tuberculosis treatments under the international DERIVE project. De Nicolò has also provided clinical consultancy in interpreting TDM results and has actively participated in the ISO certification processes for biomedical diagnostic kit validations. His extensive experience includes conducting routine drug analysis and providing clinical pharmacological advice since 2012. In addition to his research, he has taught pharmacology modules at the University of Turin for various nursing programs and a master’s course, contributing to academic education alongside his research duties.

Research Interest

Amedeo De Nicolò’s research interests lie primarily in the fields of pharmacokinetics and pharmacogenetics, focusing on clinical pharmacology. His work involves the development, validation, and application of bioanalytical methods using liquid chromatography for Therapeutic Drug Monitoring (TDM). He is particularly interested in studying drug-drug interactions, evaluating pharmacokinetic and pharmacodynamic relationships, and interpreting clinical data through statistical analysis. De Nicolò is also engaged in research related to the pharmacokinetics of antiviral treatments and the intracellular measurement of anti-infective drugs. His involvement in international research consortia, such as VirTUAL and the COVID-19 Mass Spectrometry Coalition, highlights his commitment to advancing knowledge in these areas. Additionally, De Nicolò’s research extends to the standardization of methodological approaches in TDM, contributing to the enhancement of clinical practices and patient care.

Award and Honors

Amedeo De Nicolò has received several notable awards and honors throughout his career, reflecting his significant contributions to the field of clinical pharmacology. He obtained the National Scientific Qualification as Associate Professor in the sector of Pharmacology, Clinical Pharmacology, and Pharmacognosy (05/G1) on November 6, 2018. This achievement recognizes his expertise and leadership in pharmacological research. Furthermore, De Nicolò became a licensed Biologist on August 12, 2020, showcasing his professional qualifications in biological sciences. His work is also distinguished by his active membership in prominent scientific societies, such as the Italian Society of Pharmacology (SIF) and the Italian Society of Clinical Biochemistry (SIBioC), where he continues to contribute to the advancement of pharmacological sciences.

Research skills

Amedeo De Nicolò possesses a robust set of research skills honed through extensive experience in clinical pharmacology. His expertise includes the development, validation, and application of bioanalytical methods in liquid chromatography for Therapeutic Drug Monitoring (TDM), adhering to ISO 9001 and ISO 13485 standards. He excels in pharmacokinetics and pharmacogenetics, focusing on drug interactions, efficacy, and toxicity. De Nicolò is proficient in statistical analysis and the interpretation of clinical and pharmacogenetic data. Additionally, he has a strong background in conducting and coordinating pharmacokinetic studies, including those involving intracellular drug measurements and therapeutic drug monitoring in various medical contexts. His skills are complemented by his ability to write and publish scientific articles, contributing significantly to the body of knowledge in clinical pharmacology.

Publications

  1. Pharmacogenetics of tenofovir drug transporters in the context of HBV: Is there an impact?
    • Authors: Cusato, J., Manca, A., Palermiti, A., Boglione, L., D’Avolio, A.
    • Year: 2024
    • Citations: 0
  2. Cannabinoid levels description in a cohort of patients with chronic and neuropathic pain treated with Cannabis decoction: A possible role of TDM
    • Authors: Manca, A., Valz, C., Chiara, F., Cusato, J., D’Avolio, A.
    • Year: 2024
    • Citations: 0
  3. Pharmacokinetics and Safety of Twice-daily Ritonavir-boosted Atazanavir with Rifampicin
    • Authors: Gausi, K., Mugerwa, H., Siccardi, M., Denti, P., Waitt, C.
    • Year: 2024
    • Citations: 1
  4. Comparative Performance Assessment of Novel Fluorescence Immunoassay POCTs for Measuring Circulating Levels of Vitamin-D
    • Authors: Palermiti, A., Manca, A., Mastrantonio, F., De Nicolò, A., D’Avolio, A.
    • Year: 2024
    • Citations: 0
  5. Pharmacokinetics of tecovirimat in subjects with Mpox
    • Authors: Tempestilli, M., Mondi, A., D’Avolio, A., Vaia, F., Antinori, A.
    • Year: 2024
    • Citations: 0
  6. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate in a cohort of patients with HBV infection: A retrospective study
    • Authors: Stroffolini, G., Dodaro, V., De Nicolò, A., D’Avolio, A., Boglione, L.
    • Year: 2024
    • Citations: 0
  7. Pharmacokinetics and pharmacogenetics of high-dosage tedizolid for disseminated nocardiosis in a lung transplant patient
    • Authors: Corcione, S., Vita, D., De Nicolò, A., D’Avolio, A., De Rosa, F.G.
    • Year: 2023
    • Citations: 0
  8. Experimental pharmacology in precision medicine
    • Authors: Urbaniak, A., Thummel, K.E., Alade, A.N., Sheppard, D.N., Jarvis, M.F.
    • Year: 2023
    • Citations: 1
  9. Stability Study of Fosfomycin in Elastomeric Pumps at 4 °C and 34 °C: Technical Bases for a Continuous Infusion Use for Outpatient Parenteral Antibiotic Therapy
    • Authors: Manca, A., Palermiti, A., Mula, J., De Nicolò, A., D’Avolio, A.
    • Year: 2023
    • Citations: 0
  10. Vitamin D impact in affecting clozapine plasma exposure: A potential contribution of seasonality
    • Authors: Manca, A., Mula, J., Palermiti, A., Cusato, J., D’Avolio, A.
    • Year: 2023
    • Citations: 0